The company has its own patented compounds and technologies, including MycoBank®, a genomics technology that identifies essential gene targets in fungi. F2G's drug targets the most difficult to treat fungi, especially those with the highest mortality rates, and has been designed to treat novel therapies of life-threatening invasive fungal infections. They have assembled an experienced development capacity and have received initial funding in 2002, rapidly diversifying into chemistry-driven discovery. Their antifungal screening activities enable the pharmaceutical industry and medical professionals to treat cases of fungal diseases that affect the immune system.